TRINETRA › Sectors › Healthcare
Zydus Lifesciences Limited (ZYDUSLIFE) — share price, P/E and fundamentals
Zydus Lifesciences Limited (NSE: ZYDUSLIFE) closed at ₹1,245.50 on 30 Oct 2026, +26.1% over one year, against a 52-week range of ₹835.50 – ₹1,248.90.
In the quarter ended 30 Jun 2026 (consolidated, filed 11 Aug 2026) it reported revenue of ₹8,017 cr and net profit of ₹940 cr, a 11.7% net margin; revenue grew 22.0% and profit fell 32.0% year on year.
On four consecutive filed quarters its trailing P/E is 27.5; since 20 May 2025 its own P/E has ranged from 17.5 to 27.8 (median 21.6), and today's reading is higher than 100% of those 358 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 13.9%, ROCE 15.9%, debt-to-equity 0.43, Piotroski F-score 3 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 38% of 63 sector peers; PBT margin higher than 43% of 63 sector peers; ROE higher than 51% of 63 sector peers.
Key figures
| Last close | ₹1,245.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +5.5% / +34.3% / +26.1% |
| 52-week low – high | ₹835.50 – ₹1,248.90 |
| Market capitalisation | ₹1,24,301 cr |
| Trailing P/E | 27.5 |
| Price / book | 4.58 |
| EV / EBITDA | 16.4 |
| Earnings yield | 3.6% |
| TTM EPS | ₹45.22 |
| TTM net profit | ₹4,513 cr |
| Quarter revenue | ₹8,017 cr |
| Quarter net profit | ₹940 cr |
| Net margin | 11.7% |
| Revenue growth (YoY) | +22.0% |
| Profit growth (YoY) | -32.0% |
| Return on equity | 13.9% |
| ROCE | 15.9% |
| Debt / equity | 0.43 |
| Current ratio | 1.27 |
| Free cash flow | ₹-1,277 cr |
| Piotroski F-score | 3 / 9 |
| Average daily turnover (50 days) | ₹136.1 cr |
Against Healthcare peers
| Metric | ZYDUSLIFE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.72 | 12.89 | 38 |
| PBT margin | 16.30 | 17.68 | 43 |
| ROE | 13.87 | 13.86 | 51 |
| ROCE | 15.94 | 17.26 | 41 |
| Debt / equity | 0.43 | 0.11 | 84 |
| Cash conversion | 0.41 | 1.25 | 10 |
| Trailing P/E | 27.54 | 43.26 | 19 |
| P/B | 4.58 | 6.02 | 34 |
Questions
What is the P/E ratio of Zydus Lifesciences Limited?
Zydus Lifesciences Limited's trailing P/E is 27.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 20 May 2025 its P/E has ranged 17.5–27.8.
What were Zydus Lifesciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Zydus Lifesciences Limited reported revenue of ₹8,017 cr and net profit of ₹940 cr (consolidated), filed with the exchange on 11 Aug 2026.
What is Zydus Lifesciences Limited's ROE?
Return on equity is 13.9% based on the balance sheet dated 31 Mar 2026.
Does Zydus Lifesciences Limited have debt?
Debt-to-equity is 0.43 on the balance sheet dated 31 Mar 2026.
What is ZYDUSLIFE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ZYDUSLIFE traded between ₹835.50 and ₹1,248.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.